Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATS Corporation (ATS) is an automation company. The Zacks Consensus Estimate for its current year earnings has been revised 16.7% downward over the last 60 days.BM Technologies, Inc. (BMTX) is a financial technology company. The Zacks Consensus Estimate for its current year earnings has been revised 132.1% downward over the last 60 days.Barnes Group Inc. (B) is an industrial solutions company.The Zacks Consensus Estimate for its curre ...

Tom Werner Please note all $ figures in $CAD, not $USD, unless otherwise stated Introduction I've been following shares of ATS Corporation (TSX:ATS:CA)(NYSE:ATS) for a while now. Since my initial coverage of the name back in February, I cautioned investors that while I was bullish on the company's long-term outlook regarding EVs, the valuation at 18.5x earnings wasn't providing enough margin of safety. Sure enough, with weaker auto sale volumes to start the first half of the year, shares of ATS have been un ...

Financial Data and Key Metrics - Q1 2025 order bookings were $817 million, up 18% YoY, driven by organic growth in life sciences and consumer products [7] - Q1 revenues were $694 million, down 8% YoY, primarily due to lower transportation revenues [7] - Adjusted earnings from operations in Q1 were $86 million, down 16% YoY [7] - Gross margin, excluding acquisition-related inventory fair value charges, was 29.9%, up 168 basis points YoY [20] - Backlog at the end of Q1 was $1.9 billion, with a trailing 12-month book-to-bill ratio of 1.02:1 [18] Business Line Data and Key Metrics - Life sciences backlog reached $990 million, up 26% YoY, the highest in company history [7] - Food and beverage backlog was $216 million, up 15% YoY [8] - Transportation backlog was $417 million, with smaller opportunities in the sales funnel [10] - After-sales services saw the launch of a service experience center in Cambridge, enabling real-time asset monitoring [12] Market Data and Key Metrics - Life sciences opportunity funnel remains strong, with large orders in wearable devices, GLP-1 auto-injectors, and radioisotope production lines [7][8] - Energy market opportunities include CANDU reactor refurbishment, SMRs, and energy storage [9][31] - Transportation market faces challenges, with EV projects nearing completion and reduced investments by industry participants [10] Company Strategy and Industry Competition - The company is realigning its EV business and adjusting its cost structure due to market conditions [10] - The acquisition of Paxiom is expected to enhance market position and diversify offerings in food technologies and packaging [8] - The company is focused on expanding its international customer base and leveraging its expertise in energy storage [9][31] Management Commentary on Operating Environment and Future Outlook - Management remains confident in the strategic direction, particularly in regulated end markets like life sciences [17] - The company expects Q2 revenue conversion to be in the 33% to 36% range of order backlog, with challenges in transportation [21] - Long-term growth opportunities are seen in life sciences, energy, and digital offerings [9][13] Other Important Information - The company announced the acquisition of Heidolph Instruments, a leading manufacturer of lab equipment [15] - The company launched several new products, including AI-based heat exchanger and compressor monitoring systems [13] - The company is actively engaged in M&A activities, with a diversified portfolio of target sizes and markets [15] Q&A Session Summary Question: Working Capital Situation - The increase in working capital was primarily due to timing issues in life sciences and EV projects [27] - No risk of obsolescence in the equipment being built, as contracts are being fulfilled as expected [29] Question: Energy Market Opportunities - Opportunities include CANDU reactor refurbishment, SMRs, and energy storage [31][32][33] Question: GLP-1 Market Outlook - The GLP-1 market is in line with internal expectations, with strong support for auto-injector production [35] Question: Q2 Revenue and Margin Guidance - Q2 revenue is expected to be between $620 million and $680 million, with margin pressure due to lower revenues [37][38] Question: Restructuring Actions - The company is reallocating resources and reducing workforce to align with market activity, with expected savings exceeding costs [40] Question: Life Sciences Backlog - GLP-1 orders comprise roughly 20% of the life sciences backlog [45] Question: M&A and NCIB Strategy - The company views NCIB as opportunistic and prioritizes internal investment and M&A based on return on invested capital [51] Question: Tax Rate - The effective tax rate is expected to be in the 25% to 27% range for fiscal 2025 [64] Question: Revenue Outlook - The overall revenue outlook for 2025 remains unchanged, with strong bookings in life sciences and recent acquisitions offsetting transportation declines [67] Question: Gross Margin Improvement - Gross margin improvement was driven by acquisitions, mix benefits, and easing supply chain headwinds [69]

ATS (ATS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.63%. A quarter ago, it was expected that this automation services provider would post earnings of $0.41 per share when it actually produced earnings of $0.48, delivering a surprise of 17.07%.Over the last four quarters, the ...

Exhibit 99.2 ATS CORPORATION Interim Condensed Consolidated Financial Statements For the period ended June 30, 2024 (Unaudited) ATS CORPORATION Interim Condensed Consolidated Statements of Financial Position (in thousands of Canadian dollars - unaudited) | --- | --- | --- | --- | --- | --- | |--------------------------------------------------|-----------|-------|----------------|-------|-----------------| | As at \nASSETS | Note \n11 | | June 30 2024 | | March 31 2024 | | Current assets | | | | | | | Cash a ...

ATS (ATS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expectations. O ...

 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on these positive data and pre-clinical data package demonstrating Neumifil’s activity against a broad range of viruses St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respir ...

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage bio ...

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET. The poster is titled, “Vilobelima ...

  Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted thera ...